PharmaShots | Incisive News in 3 Shots

Subscribe Now

innocare pharma

InnoCare Pharma Reports NMPA’s NDA Acceptance of Zurletrectinib to Treat NTRK Fusion-Positive Solid Tumors

InnoCare Pharma Reports NMPA’s NDA Acceptance of Zurletrectinib to Treat NTRK Fusion-Positive Solid Tumors

April 17, 2025

InnoCare Receives Approval to Initiate Clinical Evaluation of ICP-248 in Combination with Orelabrutinib for Treating Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China

InnoCare Receives Approval to Initiate Clinical Evaluation of ICP-248 in Combination with Orelabrutinib for Treating Chronic Lymph...

March 13, 2024

InnoCare Pharma Reports the IND Clearance of ICP-248 from the US FDA for Hematologic Malignancies

InnoCare Pharma Reports the IND Clearance of ICP-248 from the US FDA for Hematologic Malignancies

January 16, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us